There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Outset Medical (OM – Research Report), Cytokinetics (CYTK – Research Report) and Milestone Pharmaceuticals (MIST – Research Report) with bullish sentiments.
Outset Medical (OM)
In a report issued on May 8, Josh Jennings from TD Cowen reiterated a Buy rating on Outset Medical, with a price target of $9.00. The company’s shares closed last Monday at $3.10, close to its 52-week low of $1.92.
According to TipRanks.com, Jennings is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Outset Medical with a $6.40 average price target, which is a 106.5% upside from current levels. In a report issued on May 6, Stifel Nicolaus also maintained a Buy rating on the stock with a $6.00 price target.
See today’s best-performing stocks on TipRanks >>
Cytokinetics (CYTK)
In a report released today, Serge Belanger from Needham maintained a Buy rating on Cytokinetics, with a price target of $108.00. The company’s shares closed last Monday at $57.89.
According to TipRanks.com, Belanger is a 3-star analyst with an average return of
Cytokinetics has an analyst consensus of Strong Buy, with a price target consensus of $94.79, representing a 49.7% upside. In a report issued on May 8, Goldman Sachs also maintained a Buy rating on the stock with a $85.00 price target.
Milestone Pharmaceuticals (MIST)
In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Milestone Pharmaceuticals, with a price target of $9.00. The company’s shares closed last Monday at $1.70, close to its 52-week low of $1.33.
According to TipRanks.com, Baral is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Milestone Pharmaceuticals with a $13.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on OM:
- Outset Medical CTO Exit Amidst Cost-Cutting Restructure
- Outset Medical backs FY24 revenue view $145M-$153M, consensus $148.17M
- Outset Medical reports Q1 EPS (78c), consensus (55c)
- Outset Medical says FDA grants 510(k) clearance of TabloCart with prefiltration
- Stifel says Outset TabloCart with Prefiltration approval earlier than expected
